Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease

Pipeline Expansion of Novel Innate Defense Regulator Technology
PRINCETON, N.J., Nov. 30, 2023 /PRNewswire/ -- Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and...

Related Keywords

Turkey ,China ,Canada ,Iran ,Japan ,United Kingdom ,British ,B Brett Finlay ,Christopherj Schaber ,Robert Hancock ,Development Authority ,Exchange Commission ,Biomedical Advanced Research ,Linkedin ,Twitter ,Our Public Health Solutions ,Us Development ,Us Congress ,Prnewswire Soligenix Inc ,University Of British Columbia ,National Institute Of Allergy ,Defense Threat Reduction Agency ,Soligenix Inc ,Drug Administration ,Nasdaq ,Pipeline Expansion ,Novel Innate Defense Regulator ,Investigational New Drug ,Aphthous Ulcers ,Chief Executive Officer ,British Columbia ,Middle East ,East Asia ,Public Health Solutions ,National Institute ,Infectious Diseases ,Project Bioshield ,Priority Review Voucher ,Markets ,